Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9817182 | 0.83 | ELANE (0.49) | LMNACYP3A4ACHEELANEMEN1 | |
| SCHEMBL1171832 | 0.82 | ELANE (0.49) | LMNACYP3A4ACHEELANEMAPT | |
| SCHEMBL6972597 | 0.81 | HSD17B10 (0.40) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL10454581 | 0.80 | PAX8 (0.30) | — | |
| SCHEMBL5396445 | 0.79 | ACHE (0.43) | ACHEMAPTGAAALDH1A1MEN1 | |
| SCHEMBL4260342 | 0.79 | RAB9A (0.57) | LMNAACHEGAAALDH1A1PKM | |
| SCHEMBL7219935 | 0.79 | ELANE (0.52) | ELANE | |
| SCHEMBL128694 | 0.79 | ACHE (0.49) | LMNAACHEELANEMAPTGAA | |
| SCHEMBL6292065 | 0.79 | NCEH1 (0.40) | LMNACYP3A4ACHEMAPTGAA | |
| SCHEMBL9454285 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118281321-A | Lithium ion battery electrolyte matched with high-nickel ternary cathode material and lithium ion battery | 深圳市研一新材料有限责任公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118281320-A | Lithium ion battery electrolyte matched with high-nickel ternary cathode material-silicon-based anode material and lithium ion battery | 深圳市研一新材料有限责任公司 | 2024-07-02 | — | — | CN | claimed |
| CN-108174603-B | 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators | 阿芮纳制药有限公司 | 2021-07-02 | — | — | CN | claimed |
| EP-3292114-B1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-2814831-B1 | NEW QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF | UNIV MEDYCZNY IM KAROLA MARCINKOWSKIEGO (PL) | 2018-08-01 | — | — | EP | claimed |
| EP-3292114-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | claimed |
| US-9676758-B2 | 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto | Arena Pharmaceutical, Inc. (US) | 2017-06-13 | — | — | US | claimed |
| US-20160318911-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | US | claimed |
| WO-2016176571-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | claimed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| US-6407100-B1 | HORTICULTURE, AGRICULTURE, WOOD PRESERVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-18 | — | — | US | claimed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | claimed |
| WO-1999025707-A1 | 2-ARYLBENZO[b]THIOPHENES USEFUL FOR THE TREATMENT OF ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1999011633-A1 | TRIAZINES WITH AN ADENOSINE ANTAGONISTIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-03-11 | — | — | WO | claimed |
| EP-0238061-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS | Banyu Pharmaceutical Co., Ltd. (JP) | 1992-10-21 | — | — | EP | claimed |
| US-5011928-A | Analgesic and antiinflammatory derivatives of 1-acyl-4-arylalkylpiperazines | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMECEUTI COS S.A. (FAES) (ES) | 1991-04-30 | — | — | US | claimed |
| EP-0385043-A1 | New derivatives of 4-substituted piperazines | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-09-05 | — | — | EP | claimed |
| EP-0238061-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-09-23 | — | — | EP | claimed |
| EP-0219926-A2 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318911-A1 | 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | GPR52, HTR2A, HTR2C | LMNA 4670/4885CYP3A4 3699/4885ACHE 3393/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | LMNA 2398/4885CYP3A4 988/4885ACHE 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.